387 related articles for article (PubMed ID: 18156614)
1. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
Eur Heart J; 2008 Jan; 29(2):166-76. PubMed ID: 18156614
[TBL] [Abstract][Full Text] [Related]
2. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.
Malmberg K; Rydén L; Wedel H; Birkeland K; Bootsma A; Dickstein K; Efendic S; Fisher M; Hamsten A; Herlitz J; Hildebrandt P; MacLeod K; Laakso M; Torp-Pedersen C; Waldenström A;
Eur Heart J; 2005 Apr; 26(7):650-61. PubMed ID: 15728645
[TBL] [Abstract][Full Text] [Related]
3. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart.
Anselmino M; Ohrvik J; Malmberg K; Standl E; Rydén L;
Eur Heart J; 2008 Jan; 29(2):177-84. PubMed ID: 18156611
[TBL] [Abstract][Full Text] [Related]
4. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
Schramm TK; Gislason GH; Køber L; Rasmussen S; Rasmussen JN; Abildstrøm SZ; Hansen ML; Folke F; Buch P; Madsen M; Vaag A; Torp-Pedersen C
Circulation; 2008 Apr; 117(15):1945-54. PubMed ID: 18378618
[TBL] [Abstract][Full Text] [Related]
5. Effect of gender on prognosis in patients with myocardial infarction and type 2 diabetes.
Venskutonyte L; Malmberg K; Norhammar A; Wedel H; Rydén L
J Intern Med; 2010 Jul; 268(1):75-82. PubMed ID: 20210844
[TBL] [Abstract][Full Text] [Related]
6. [Metabolic control by means of insulin in patients with type 2 diabetes and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity--secondary publication].
Gustafsson I; Malmberg K; Rydén L; Wedel H; Birkeland K; Bootsma A; Dickstein K; Efendic S; Fisher M; Hamsten A; Herlitz J; Hildebrandt PR; MacLeod K; Laakso M; Torp-Pedersen CT; Waldenström A;
Ugeskr Laeger; 2006 Feb; 168(6):581-4. PubMed ID: 16476220
[TBL] [Abstract][Full Text] [Related]
7. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA).
Meier JJ; Deifuss S; Klamann A; Schmiegel W; Nauck MA;
Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):344-50. PubMed ID: 14520601
[TBL] [Abstract][Full Text] [Related]
8. The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes: a report from the DIGAMI 2 trial.
Mellbin LG; Malmberg K; Rydén L; Wedel H; Vestberg D; Lind M
Eur Heart J; 2013 Feb; 34(5):374-9. PubMed ID: 23144046
[TBL] [Abstract][Full Text] [Related]
9. Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.
Horsdal HT; Mehnert F; Rungby J; Johnsen SP
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):717-25. PubMed ID: 21536457
[TBL] [Abstract][Full Text] [Related]
10. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
11. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.
Schramm TK; Gislason GH; Vaag A; Rasmussen JN; Folke F; Hansen ML; Fosbøl EL; Køber L; Norgaard ML; Madsen M; Hansen PR; Torp-Pedersen C
Eur Heart J; 2011 Aug; 32(15):1900-8. PubMed ID: 21471135
[TBL] [Abstract][Full Text] [Related]
12. Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: a report from the Swedish National Diabetes Register.
Nilsson PM; Cederholm J; Eeg-Olofsson K; Eliasson B; Zethelius B; Fagard R; Gudbjörnsdóttir S;
Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):506-12. PubMed ID: 19561510
[TBL] [Abstract][Full Text] [Related]
13. Glucose-lowering therapy after myocardial infarction: more questions than answers.
Radke PW; Schunkert H
Eur Heart J; 2008 Jan; 29(2):141-3. PubMed ID: 18199566
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study.
Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
Diabetologia; 2011 Jun; 54(6):1308-17. PubMed ID: 21359582
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial.
Mellbin LG; Malmberg K; Waldenström A; Wedel H; Rydén L;
Heart; 2009 May; 95(9):721-7. PubMed ID: 19029171
[TBL] [Abstract][Full Text] [Related]
16. Effects of fasting blood glucose levels and blood pressure and treatment of diabetes and hypertension on the incidence of cardiovascular disease: a study of 740 patients with incident Type 2 diabetes with up to 30 years' follow-up.
Jansson SP; Svärdsudd K; Andersson DK
Diabet Med; 2014 Sep; 31(9):1055-63. PubMed ID: 24894815
[TBL] [Abstract][Full Text] [Related]
17. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
18. Leptin: a predictor of abnormal glucose tolerance and prognosis in patients with myocardial infarction and without previously known Type 2 diabetes.
Wallander M; Söderberg S; Norhammar A
Diabet Med; 2008 Aug; 25(8):949-55. PubMed ID: 18959608
[TBL] [Abstract][Full Text] [Related]
19. IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes.
Wallander M; Norhammar A; Malmberg K; Ohrvik J; Rydén L; Brismar K
Diabetes Care; 2007 Sep; 30(9):2343-8. PubMed ID: 17563335
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.
Masoudi FA; Inzucchi SE; Wang Y; Havranek EP; Foody JM; Krumholz HM
Circulation; 2005 Feb; 111(5):583-90. PubMed ID: 15699279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
